Quote Havasu78
"-CD16 - Slam dunk trial will take care of the above if not granted sooner "
I thought I heard CD12 was a slam dunk.
Based on the under CD12 under 65 data, CD16 certainly appears a slam dunk
We It’s more of a slam dunk because we are not using mortality for a primary end point. We tested very very good for 6 day early release from hospital. That will be our primary end point. New change is adding the break at 65 years old into two trials instead of one to add to the slam dunk. It’s a great idea and I wonder who thought of this? Dr. Kelly? Dr Rahman?
Quote Havasu78
What I fear is that Patterson has lab data which might demonstrate that result but CYDY doesn't want to pay Patterson for the data.
We haven’t needed any lab work from Doctor Patterson’s lab for what? A year?
Last thing we might of needed was RO testing but that wasn’t performed to FDA standards and wasn’t any good for us. That’s why we hired another vendor to accomplish the RO and Nader stated this clearly in the last CC. Also stated that RO testing will be complete soon and we will file HIV BLAs across the board for Duel and Mono by end of July. This is great news and will give us revenue this year in HIV in some locations if approved. My bet is Dr. Rahman slam dunks these HIV BLAs or equivalent in the 4-5 countries we mentioned in the CC.
I am wondering if you listened to the CC for the latest updates. Because the subjects you mentioned were all spoken about in the latest CC. Just thought I would give you a heads up. You can still access the CC on Cytodyn’s web site.
Read More: https://investorshangout.com/post/newpost/605...z6pzxakz8h
Read More: https://investorshangout.com/post/newpost/605...z6pzvqLo85
"-CD16 - Slam dunk trial will take care of the above if not granted sooner "
I thought I heard CD12 was a slam dunk.
Based on the under CD12 under 65 data, CD16 certainly appears a slam dunk
We It’s more of a slam dunk because we are not using mortality for a primary end point. We tested very very good for 6 day early release from hospital. That will be our primary end point. New change is adding the break at 65 years old into two trials instead of one to add to the slam dunk. It’s a great idea and I wonder who thought of this? Dr. Kelly? Dr Rahman?
Quote Havasu78
What I fear is that Patterson has lab data which might demonstrate that result but CYDY doesn't want to pay Patterson for the data.
We haven’t needed any lab work from Doctor Patterson’s lab for what? A year?
Last thing we might of needed was RO testing but that wasn’t performed to FDA standards and wasn’t any good for us. That’s why we hired another vendor to accomplish the RO and Nader stated this clearly in the last CC. Also stated that RO testing will be complete soon and we will file HIV BLAs across the board for Duel and Mono by end of July. This is great news and will give us revenue this year in HIV in some locations if approved. My bet is Dr. Rahman slam dunks these HIV BLAs or equivalent in the 4-5 countries we mentioned in the CC.
I am wondering if you listened to the CC for the latest updates. Because the subjects you mentioned were all spoken about in the latest CC. Just thought I would give you a heads up. You can still access the CC on Cytodyn’s web site.
Read More: https://investorshangout.com/post/newpost/605...z6pzxakz8h
Read More: https://investorshangout.com/post/newpost/605...z6pzvqLo85
3
